Premium
Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work
Author(s) -
Koya Yudai,
Shibata Michihiko,
Shinohara Nobuhiko,
Nebuya Satoru,
Oe Shinji,
Honma Yuichi,
Senju Michio,
Sato Naoko,
Harada Masaru
Publication year - 2019
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13329
Subject(s) - pembrolizumab , medicine , bile duct , gastroenterology , lung , radiology , general surgery , cancer , immunotherapy
A 66‐year‐old man was admitted to our department due to cholestatic liver injury. He had received five cycles of pembrolizumab for small‐cell lung cancer. Imaging showed the possibility of sclerosing cholangitis (SC) with hemobilia. Histologically, CD8 + T cells had infiltrated the biliary epithelium of the extrahepatic bile duct. We reached the diagnosis of secondary SC induced by pembrolizumab. Although we treated him with high‐dose corticosteroids, laboratory data showed only a moderate response. Clinicians should recognize that immune checkpoint inhibitors can sometimes cause severe and irreversible SC.